-+ 0.00%
-+ 0.00%
-+ 0.00%
Orient (605116.SH) subsidiary estradiol didrogesterone tablets obtained drug registration certificate
Share
Listen to the news

Zhitong Finance App News, Orient (605116.SH) issued an announcement. Recently, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an estradiol didroprogesterone tablet “Drug Registration Certificate” approved and issued by the State Drug Administration. This drug is a hormone replacement therapy (HRT) medication and is suitable for treating symptoms of oestrogen deficiency in women at least 12 months after menopause.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending